Carfilzomib, a selective proteasome inhibitor, is marketed by Onyx Pharmaceuticals under the name Kyprolis. FDA approved the epoxomicin derivative in July 2012 for treating patients with relapsed, refractory multiple myeloma. Work by C. M. Crews and co-workers at Yale University led directly to the development of carfilzomib.
Learn more about this molecule from CAS, the most authoritative and comprehensive source for chemical information.
Stay Ahead of the Chemistry Curve
Learn how ACS can help you stay ahead in the world of chemistry.